<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269801</url>
  </required_header>
  <id_info>
    <org_study_id>JUVE_BTX-09-01</org_study_id>
    <nct_id>NCT01269801</nct_id>
  </id_info>
  <brief_title>Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds</brief_title>
  <acronym>JUVE_BTX</acronym>
  <official_title>A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AboutSkin Dermatology and DermSurgery, PC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AboutSkin Dermatology and DermSurgery, PC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and
      BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment
      of age-associated wrinkles and folds of the face.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Compounds:

             1. BOTOX Cosmetic (onabotulinumtoxinA) for Injection

             2. JUVEDERM Ultra XC and JUVEDERM Ultra Plus XC Injectable Gel

        2. The objectives of this study are:

             1. To assess physician assessment of efficacy and incremental benefit following BOTOX
                Cosmetic and Juvederm for the treatment of moderate to severe facial wrinkles and
                folds;

             2. To assess patient perceptions of treatment outcomes and incremental benefit
                following BOTOX Cosmetic and Juvederm for the treatment of moderate to severe
                facial wrinkles and folds.

        3. Investigator and study sites:

             1. multicenter study

             2. 5 Sites: 2 in US, 2 in Canada, 1 in EU
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Week 4, 8, 12, 24</time_frame>
    <description>Assessments at Visits 3,5,6+7 (weeks 4,8,12,24) include:
-Physician Global Aesthetic Improvement Scale (PGAIS). Ratings include no change, improved, much improved, very much improved.
Number of subjects with improvement score for the 5 point PGAIS from baseline to Visit 7.
-Objective Observer Global Aesthetic Improvement Scale Number of subjects with improvement score for the from baseline to Visit 7. Ratings include no change, some improvement, definite improvement, substantial improvement, and complete improvement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Botox Cosmetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>onabotulinumtoxinA for injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JUVÉDERM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;
Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.</description>
    <arm_group_label>Botox Cosmetic</arm_group_label>
    <other_name>Europe Investigative Sites:</other_name>
    <other_name>VISTABEL® (Botulinum toxin type A) for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JUVÉDERM</intervention_name>
    <description>Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;
• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.</description>
    <arm_group_label>JUVÉDERM</arm_group_label>
    <other_name>EU Investigative Sites:</other_name>
    <other_name>JUVÉDERM® Ultra 2 and JUVÉDERM® Ultra 3 Injectable Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult females or males, aged 25 to 65 years;

          -  Subjects must be seeking treatment with either BOTOX® or JUVÉDERM injections;

          -  Subjects must have one or more moderate to severe hyperfunctional facial lines of the
             upper face (i.e., glabellar lines, lateral canthal lines (crow's feet) or horizontal
             forehead lines) or moderate to severe nasolabial folds based on the physician observer
             assessment (0-3 scale);

          -  Women must either be of non-childbearing potential (i.e., surgically sterilized or
             post-menopausal) or if of childbearing potential, must not be pregnant (as documented
             by a negative urine pregnancy test at the baseline examination) or lactating and must
             be practicing a medically acceptable method of birth control;

          -  Subjects must be willing and able to provide written informed consent;

          -  Subjects must be willing and able to follow the procedures outlined in this protocol.

        Exclusion Criteria:

          -  Female subjects who are pregnant (positive urine pregnancy test) or who have an infant
             they are breast-feeding or who are of childbearing potential and not practicing a
             reliable method of birth control;

          -  Previous botulinum toxin or semipermanent injectable filler therapy within the past
             year or any prior history of permanent filler therapy injection;

          -  Prior cosmetic procedures (i.e., liposuction, etc.) or visible scars that may affect
             evaluation of response and/or quality of photography;

          -  Known allergy or sensitivity to any of the study medication or their components;

          -  Known severe allergies manifested by a history of anaphylaxis or history or presence
             of multiple severe allergies;

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
             or any other disease that might interfere with neuromuscular function;

          -  Concurrent use of aminoglycoside antibiotics that interfere with neuromuscular
             function;

          -  Subjects with profound atrophy or excessive weakness of the muscles in the target
             area(s) of BOTOX injection;

          -  Subjects with an infection at an injection site or systemic infection (in this case,
             postpone study entry until one week following recovery);

          -  Concurrent participation in an investigational drug or device study or participation
             within 30 days of study start;

          -  Subjects are not to undergo any additional cosmetic procedures during the study
             period;

          -  Subjects are not to change use of any facial products up to 6 months prior to
             enrollment and during study period;

          -  Subjects with a history of poor cooperation, non-compliance with medical treatment, or
             unreliability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel L Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AboutSkin Dermatology and DermSurgery, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>About Skin Dermatology</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Falls Dermantology and Skin Care Center</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2E 7H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <results_first_submitted>July 11, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AboutSkin Dermatology and DermSurgery, PC</investigator_affiliation>
    <investigator_full_name>AboutSkin Dermatology</investigator_full_name>
    <investigator_title>Joel L. Cohen, MD</investigator_title>
  </responsible_party>
  <keyword>BOTOX</keyword>
  <keyword>JUVEDERM</keyword>
  <keyword>Prospective</keyword>
  <keyword>Open Label</keyword>
  <keyword>Randomized</keyword>
  <keyword>Crossover Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects were randomized to two groups: Juvederm first, then Botox (Juvederm group) or Botox first, then Juvederm (Botox group).
For the Juvederm group, Day 1 involved juvederm treatment. Week 4 involved botox administration.
For the Botox group, Day 1 involved botox treatment. Week 4 involved juvederm administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JUVÉDERM</title>
          <description>JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
Juvederm group will initially receive JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions at Day 1.
At Week 4, patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.</description>
        </group>
        <group group_id="P2">
          <title>Botox Cosmetic</title>
          <description>Botox group will initially receive BOTOX® Cosmetic injections to the affected facial regions at Day 1.
At Week 4, patients who initially received BOTOX® Cosmetic treatment will be crossed over to receive JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis stratified by treatment group (per sequence).</population>
      <group_list>
        <group group_id="B1">
          <title>Botox Cosmetic</title>
          <description>Botox group will initially receive BOTOX® Cosmetic injections to the affected facial regions at Day 1.
At Week 4, patients who initially received BOTOX® Cosmetic treatment will be crossed over to receive JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel treatment.</description>
        </group>
        <group group_id="B2">
          <title>JUVÉDERM</title>
          <description>JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
Juvederm group will initially receive JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions at Day 1.
At Week 4, patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.83" spread="7.42"/>
                    <measurement group_id="B2" value="51.12" spread="7.78"/>
                    <measurement group_id="B3" value="50.54" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy</title>
        <description>Assessments at Visits 3,5,6+7 (weeks 4,8,12,24) include:
-Physician Global Aesthetic Improvement Scale (PGAIS). Ratings include no change, improved, much improved, very much improved.
Number of subjects with improvement score for the 5 point PGAIS from baseline to Visit 7.
-Objective Observer Global Aesthetic Improvement Scale Number of subjects with improvement score for the from baseline to Visit 7. Ratings include no change, some improvement, definite improvement, substantial improvement, and complete improvement.</description>
        <time_frame>Week 4, 8, 12, 24</time_frame>
        <population>Analysis is based on the randomization group to account for the order in which the products were administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Botox Cosmetic</title>
            <description>Botox group will initially receive BOTOX® Cosmetic injections to the affected facial regions at Day 1.
At Week 4, patients who initially received BOTOX® Cosmetic treatment will be crossed over to receive JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel treatment.</description>
          </group>
          <group group_id="O2">
            <title>JUVÉDERM</title>
            <description>JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
Juvederm group will initially receive JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions at Day 1.
At Week 4, patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy</title>
          <description>Assessments at Visits 3,5,6+7 (weeks 4,8,12,24) include:
-Physician Global Aesthetic Improvement Scale (PGAIS). Ratings include no change, improved, much improved, very much improved.
Number of subjects with improvement score for the 5 point PGAIS from baseline to Visit 7.
-Objective Observer Global Aesthetic Improvement Scale Number of subjects with improvement score for the from baseline to Visit 7. Ratings include no change, some improvement, definite improvement, substantial improvement, and complete improvement.</description>
          <population>Analysis is based on the randomization group to account for the order in which the products were administered.</population>
          <units>participantes rated improved and higher</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PGAIS Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Objective Observer global assessment Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAIS Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Objective Observer global assessment Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAIS Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Objective Observer global assessment Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGAIS Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Objective Observer global assessment Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 4, 8, 12, 24</time_frame>
      <desc>Adverse Events assessed based on treatment received before the adverse event onset.</desc>
      <group_list>
        <group group_id="E1">
          <title>Botox Cosmetic</title>
          <description>Botox group will initially receive BOTOX® Cosmetic injections to the affected facial regions at Day 1.
At Week 4, patients who initially received BOTOX® Cosmetic treatment will be crossed over to receive JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel treatment.</description>
        </group>
        <group group_id="E2">
          <title>JUVÉDERM</title>
          <description>JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
Juvederm group will initially receive JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions at Day 1.
At Week 4, patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>death due to hypertensive cardiovascular disease</sub_title>
                <description>Subject died 2 months after last study visit, approximately 1.5 months after last juvederm injection. Investigator assessed as not related to study treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Paresis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>(Contusion) Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joel L. Cohen, MD</name_or_title>
      <organization>AboutSkin</organization>
      <phone>303-756-7546</phone>
      <email>research@aboutskinderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

